Literature DB >> 24141982

Comparison of the live attenuated yellow fever vaccine 17D-204 strain to its virulent parental strain Asibi by deep sequencing.

Andrew Beck1, Robert B Tesh, Thomas G Wood, Steven G Widen, Kate D Ryman, Alan D T Barrett.   

Abstract

BACKGROUND: The first comparison of a live RNA viral vaccine strain to its wild-type parental strain by deep sequencing is presented using as a model the yellow fever virus (YFV) live vaccine strain 17D-204 and its wild-type parental strain, Asibi.
METHODS: The YFV 17D-204 vaccine genome was compared to that of the parental strain Asibi by massively parallel methods. Variability was compared on multiple scales of the viral genomes. A modeled exploration of small-frequency variants was performed to reconstruct plausible regions of mutational plasticity.
RESULTS: Overt quasispecies diversity is a feature of the parental strain, whereas the live vaccine strain lacks diversity according to multiple independent measurements. A lack of attenuating mutations in the Asibi population relative to that of 17D-204 was observed, demonstrating that the vaccine strain was derived by discrete mutation of Asibi and not by selection of genomes in the wild-type population.
CONCLUSIONS: Relative quasispecies structure is a plausible correlate of attenuation for live viral vaccines. Analyses such as these of attenuated viruses improve our understanding of the molecular basis of vaccine attenuation and provide critical information on the stability of live vaccines and the risk of reversion to virulence.

Entities:  

Keywords:  17D, Viral Population; Deep Sequencing; Flavivirus; Parallel Sequencing; Quasispecies; Vaccine; Variants; Yellow Fever Virus

Mesh:

Substances:

Year:  2013        PMID: 24141982      PMCID: PMC3883177          DOI: 10.1093/infdis/jit546

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  38 in total

1.  Quasispecies diversity determines pathogenesis through cooperative interactions in a viral population.

Authors:  Marco Vignuzzi; Jeffrey K Stone; Jamie J Arnold; Craig E Cameron; Raul Andino
Journal:  Nature       Date:  2005-12-04       Impact factor: 49.962

Review 2.  RNA virus populations as quasispecies.

Authors:  J J Holland; J C De La Torre; D A Steinhauer
Journal:  Curr Top Microbiol Immunol       Date:  1992       Impact factor: 4.291

Review 3.  The top five "game changers" in vaccinology: toward rational and directed vaccine development.

Authors:  Richard B Kennedy; Gregory A Poland
Journal:  OMICS       Date:  2011-08-04

4.  Numerical index of the discriminatory ability of typing systems: an application of Simpson's index of diversity.

Authors:  P R Hunter; M A Gaston
Journal:  J Clin Microbiol       Date:  1988-11       Impact factor: 5.948

5.  High stability of yellow fever 17D-204 vaccine: a 12-year restrospective analysis of large-scale production.

Authors:  V Barban; Y Girerd; M Aguirre; S Gulia; F Pétiard; P Riou; B Barrere; J Lang
Journal:  Vaccine       Date:  2006-08-01       Impact factor: 3.641

6.  Maximum-likelihood estimation of phylogeny from DNA sequences when substitution rates differ over sites.

Authors:  Z Yang
Journal:  Mol Biol Evol       Date:  1993-11       Impact factor: 16.240

7.  Viral nucleic acids in live-attenuated vaccines: detection of minority variants and an adventitious virus.

Authors:  Joseph G Victoria; Chunlin Wang; Morris S Jones; Crystal Jaing; Kevin McLoughlin; Shea Gardner; Eric L Delwart
Journal:  J Virol       Date:  2010-04-07       Impact factor: 5.103

8.  Comparison of the genomes of the wild-type French viscerotropic strain of yellow fever virus with its vaccine derivative French neurotropic vaccine.

Authors:  E Wang; K D Ryman; A D Jennings; D J Wood; F Taffs; P D Minor; P G Sanders; A D Barrett
Journal:  J Gen Virol       Date:  1995-11       Impact factor: 3.891

9.  E protein domain III determinants of yellow fever virus 17D vaccine strain enhance binding to glycosaminoglycans, impede virus spread, and attenuate virulence.

Authors:  Eva Lee; Mario Lobigs
Journal:  J Virol       Date:  2008-04-09       Impact factor: 5.103

10.  A wide extent of inter-strain diversity in virulent and vaccine strains of alphaherpesviruses.

Authors:  Moriah L Szpara; Yolanda R Tafuri; Lance Parsons; S Rafi Shamim; Kevin J Verstrepen; Matthieu Legendre; L W Enquist
Journal:  PLoS Pathog       Date:  2011-10-13       Impact factor: 6.823

View more
  39 in total

1.  Genotypic and phenotypic characterization of West Nile virus NS5 methyltransferase mutants.

Authors:  Jaclyn A Kaiser; Huanle Luo; Steven G Widen; Thomas G Wood; Claire Y-H Huang; Tian Wang; Alan D T Barrett
Journal:  Vaccine       Date:  2019-10-11       Impact factor: 3.641

2.  Plasmid DNA initiates replication of yellow fever vaccine in vitro and elicits virus-specific immune response in mice.

Authors:  Irina Tretyakova; Brian Nickols; Rachmat Hidajat; Jenny Jokinen; Igor S Lukashevich; Peter Pushko
Journal:  Virology       Date:  2014-08-16       Impact factor: 3.616

Review 3.  Broad-spectrum agents for flaviviral infections: dengue, Zika and beyond.

Authors:  Veaceslav Boldescu; Mira A M Behnam; Nikos Vasilakis; Christian D Klein
Journal:  Nat Rev Drug Discov       Date:  2017-05-05       Impact factor: 84.694

Review 4.  Live Attenuated Yellow Fever 17D Vaccine: A Legacy Vaccine Still Controlling Outbreaks In Modern Day.

Authors:  Natalie D Collins; Alan D T Barrett
Journal:  Curr Infect Dis Rep       Date:  2017-03       Impact factor: 3.725

5.  Yellow fever vaccine-associated neurological disease: it is not just the silver generation at risk.

Authors:  Emily J Goldstein; David J Bell; Rory N Gunson
Journal:  BMJ Case Rep       Date:  2019-05-13

6.  A Single Amino Acid Substitution in the M Protein Attenuates Japanese Encephalitis Virus in Mammalian Hosts.

Authors:  Mélissanne de Wispelaere; Cécile Khou; Marie-Pascale Frenkiel; Philippe Desprès; Nathalie Pardigon
Journal:  J Virol       Date:  2015-12-09       Impact factor: 5.103

Review 7.  Current status and future prospects of yellow fever vaccines.

Authors:  Andrew S Beck; Alan D T Barrett
Journal:  Expert Rev Vaccines       Date:  2015-09-14       Impact factor: 5.217

8.  Development of a Real-Time Reverse Transcription-PCR Assay for Global Differentiation of Yellow Fever Virus Vaccine-Related Adverse Events from Natural Infections.

Authors:  Holly R Hughes; Brandy J Russell; Eric C Mossel; John Kayiwa; Julius Lutwama; Amy J Lambert
Journal:  J Clin Microbiol       Date:  2018-05-25       Impact factor: 5.948

Review 9.  Yellow Fever Virus: Knowledge Gaps Impeding the Fight Against an Old Foe.

Authors:  Florian Douam; Alexander Ploss
Journal:  Trends Microbiol       Date:  2018-06-19       Impact factor: 17.079

10.  Measurements of Intrahost Viral Diversity Are Extremely Sensitive to Systematic Errors in Variant Calling.

Authors:  John T McCrone; Adam S Lauring
Journal:  J Virol       Date:  2016-07-11       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.